Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arcus BiosciencesRCUS +0.80%49 12-1 Month Momentum % is 215.72% as of Aug. 12, 2026. GuruFocus rates RCUS with a GF Score™ of 49/100 and a GF Value™ of $7.23 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,352 Biotechnology companies, Arcus Biosciences ranks better than 94.16% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-12), Arcus Biosciences's 12-1 Month Momentum % is 215.72%.
The industry rank for Arcus Biosciences's 12-1 Month Momentum % or its related term are showing as below:
RCUS's 12-1 Month Momentum % is ranked better than 94.16% of 1352
companies
in the Biotechnology industry
Industry Median: -14.77
vs RCUS: 215.72
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Arcus Biosciences 12-1 Month Momentum % Related Terms
RCUS vs ALMS, DNLI, NAMS: 12-1 Month Momentum % Comparison
For the Biotechnology subindustry, Arcus Biosciences's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcus Biosciences 12-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arcus Biosciences's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Arcus Biosciences's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of 215.72% mean?
Arcus Biosciences (RCUS) has a 12-1 Month Momentum % of 215.72% as of Aug. 12, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Arcus Biosciences and its competitors. According to the industry distribution chart, Arcus Biosciences ranks #79 out of 1352 companies in the Biotechnology industry, placing it in the top 5.8%.
Is Arcus Biosciences' 12-1 Month Momentum % too high?
Arcus Biosciences' current 12-1 Month Momentum % is 215.72%. Based on the distribution chart, Arcus Biosciences ranks #79 out of 1352 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arcus Biosciences has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcus Biosciences' 12-1 Month Momentum % compare to ALMS and DNLI?
According to the Biotechnology industry distribution chart, Arcus Biosciences ranks #79 out of 1352 companies for 12-1 Month Momentum %. This places Arcus Biosciences in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Arcus Biosciences and its competitors. Arcus Biosciences's current 12-1 Month Momentum % is 215.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcus Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Arcus Biosciences (RCUS) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.23, compared to a current price of $28.97 — trading 300.7% above its estimated fair value. The current 12-1 Month Momentum % is 215.72%. Arcus Biosciences' overall GF Score™ is 49/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Arcus Biosciences (RCUS), the current 12-1 Month Momentum % is 215.72% as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcus Biosciences (RCUS) Overvalued in 2026?
Based on GuruFocus' analysis, Arcus Biosciences stock appears to be overvalued.
The current stock price of $28.97 is trading 300.7% above its estimated GF Value™ of $7.23.
GuruFocus considers Arcus Biosciences to be Significantly Overvalued.
Key valuation signals for RCUS:
12-1 Month Momentum %: 215.72%
GF Value™: $7.23 vs. price of $28.97 (300.7% above fair value)
No single metric tells the full story. See the RCUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
49GF Score
Get the complete analysis for RCUS
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RCUS has been successfully added to your 
